Kochi (Kerala): Circulating tumour DNA (ctDNA) tests could bring major changes to early cancer detection and cancer treatment as they become more accessible and affordable in India, cancer experts said at the Aster Quality Care Cancer Conclave (AQCCON) 2026, which began in Kochi on Friday.

The advanced blood test can detect tumour-related genetic mutations at an early stage, potentially allowing cancer to be identified before tumours become detectable through conventional scans. Experts noted that the growing availability of ctDNA testing in Indian laboratories is helping bring down costs, though validation is needed to optimise the tests' sensitivity and specificity.

The three-day conclave, organised by the Aster International Institute of Oncology at Kochi, features more than 60 academic sessions involving cancer specialists from across the country. Sessions focus on areas including genomic oncology and hereditary cancers, with experts also addressing misconceptions and concerns surrounding cancers that may run in families.

Dr Arun R. Warrier, organising secretary of AQCCON and senior consultant in medical oncology at Aster Medcity, said the conclave aims to bring cancer specialists together to share new ideas and innovations and improve treatment outcomes.

Expert panel discussions, case-based debates and clinical research presentations will continue during the conclave.